Mydecine Innovations Group Inc.

United States of America

Back to Profile

1-34 of 34 for Mydecine Innovations Group Inc. Sort by
Query
Aggregations
IP Type
        Patent 26
        Trademark 8
Jurisdiction
        United States 19
        World 9
        Canada 6
Date
2024 December 1
2024 7
2023 14
2022 11
2020 2
IPC Class
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin 8
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca 6
A61P 25/00 - Drugs for disorders of the nervous system 5
C07D 209/16 - Tryptamines 5
A61K 31/33 - Heterocyclic compounds 4
See more
NICE Class
42 - Scientific, technological and industrial services, research and design 8
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 8
Status
Pending 14
Registered / In Force 20

1.

SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE

      
Application Number 18227186
Status Pending
Filing Date 2023-07-27
First Publication Date 2024-12-05
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

IPC Classes  ?

  • C07D 277/62 - Benzothiazoles
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

2.

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

      
Application Number 18405189
Status Pending
Filing Date 2024-01-05
First Publication Date 2024-06-20
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

IPC Classes  ?

  • A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

3.

Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same

      
Application Number 18443025
Status Pending
Filing Date 2024-02-15
First Publication Date 2024-06-20
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

4.

Aza-substituted psilocin analogs and methods of synthesizing the same

      
Application Number 18386021
Grant Number 11939292
Status In Force
Filing Date 2023-11-01
First Publication Date 2024-03-26
Grant Date 2024-03-26
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

5.

SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE

      
Document Number 03232547
Status Pending
Filing Date 2023-06-13
Open to Public Date 2024-03-14
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

IPC Classes  ?

  • A61K 31/13 - Amines, e.g. amantadine
  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/4743 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
  • C07D 263/54 - BenzoxazolesHydrogenated benzoxazoles
  • C07D 263/52 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems

6.

SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE

      
Application Number US2023025197
Publication Number 2024/054279
Status In Force
Filing Date 2023-06-13
Publication Date 2024-03-14
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton, W.
  • Roscow, Robert, F.
  • Ling, Rong
  • Gao, Chuanjun

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.

IPC Classes  ?

  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/4743 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
  • A61K 31/13 - Amines, e.g. amantadine
  • C07D 263/54 - BenzoxazolesHydrogenated benzoxazoles
  • A61K 31/33 - Heterocyclic compounds
  • C07D 263/52 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems

7.

PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME

      
Application Number 18226767
Status Pending
Filing Date 2023-07-26
First Publication Date 2024-01-18
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abstract

The present invention includes a novel class of MDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

IPC Classes  ?

  • C07D 317/58 - Radicals substituted by nitrogen atoms
  • C07D 327/04 - Five-membered rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

8.

NOVEL FUNGAL COMPOIND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE

      
Application Number 18032922
Status Pending
Filing Date 2021-10-28
First Publication Date 2023-12-14
Owner Mydecine Innovations Group Inc. (USA)
Inventor Roscow, Robert F.

Abstract

The present invention further relates generally to novel systems, methods, and compositions for generating pharmaceutical compositions and formulations that include one or more fungal compounds and/or extracts.

IPC Classes  ?

  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
  • A61K 36/068 - Cordyceps
  • A61K 36/074 - Ganoderma
  • A61K 36/07 - Basidiomycota, e.g. Cryptococcus

9.

NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF

      
Application Number 18029543
Status Pending
Filing Date 2021-10-01
First Publication Date 2023-11-16
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Gustin, John C
  • Mccarthy, Michael J

Abstract

The present invention provides compositions and methods for the treatment of a serotonin receptor related disease or condition in a subject in need thereof. A composition of the invention includes at least one psychedelic compound, which is preferably a serotonin receptor agonist, and at least one secondary agent that modulates the activity of the serotonin receptor agonist, or the physiological response to the serotonin receptor agonist in the subject.

IPC Classes  ?

  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/70 - CarbohydratesSugarsDerivatives thereof
  • A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
  • A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
  • A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
  • A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
  • A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
  • A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione

10.

NOVEL PSILOCIN PRODRUG COMPOUNDS AND METHODS OF SYNTHESIZING THE SAME

      
Application Number US2023019714
Publication Number 2023/219789
Status In Force
Filing Date 2023-04-25
Publication Date 2023-11-16
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abstract

in vivo. in vivo.

IPC Classes  ?

  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/13 - Amines, e.g. amantadine
  • A61K 31/33 - Heterocyclic compounds

11.

NOVEL PSILOCIN PRODRUG COMPOUNDS AND METHODS OF SYNTHESIZING THE SAME

      
Document Number 03224835
Status Pending
Filing Date 2023-04-25
Open to Public Date 2023-11-16
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention includes a novel class of psilocin carbamates and carbonate prodrug compounds having one or more aza substitution within the psilocin core. The psilocin prodrugs of the invention are enzymatically cleaved in vivo.

IPC Classes  ?

  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin

12.

Aza-substituted psilocin analogs and methods of synthesizing the same

      
Application Number 18142010
Grant Number 11952342
Status In Force
Filing Date 2023-05-01
First Publication Date 2023-11-02
Grant Date 2024-04-09
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

13.

Novel Formulations of Psilocybin And Psilocin Compounds as Serotonin Agonists in Combination With 3,4 Methylenedioxymethamphetamine (MDMA)

      
Application Number 18026780
Status Pending
Filing Date 2021-09-18
First Publication Date 2023-11-02
Owner Mydecine Innovations Group Inc. (USA)
Inventor Roscow, Robert Fletcher

Abstract

The present invention is directed to the use of psilocybin and/or psilocin compounds in combination with 3,4-methylenedioxymethamphetamine (MDMA) or other entactogens, to modulate activity of serotonin receptors, and preferably the 5-HT2A serotonin receptor in humans. In certain preferred embodiment, the co-formulation of psilocybin and/or psilocin compounds in combination with MDMA may result in complex modulation activity of serotonin receptors in a subject in need thereof, and may be uses as a therapeutic treatment for one or more serotonin receptor related diseases or conditions.

IPC Classes  ?

  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin

14.

Short-acting psychoactive compounds of the MDMA class

      
Application Number 18209334
Grant Number 11896577
Status In Force
Filing Date 2023-06-13
First Publication Date 2023-10-12
Grant Date 2024-02-13
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.
  • Ling, Rong
  • Gao, Chuanjun

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

IPC Classes  ?

  • A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

15.

NOVEL PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME

      
Document Number 03218730
Status Pending
Filing Date 2023-02-27
Open to Public Date 2023-08-31
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention includes a novel class ofMDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

IPC Classes  ?

  • C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin

16.

Novel Psilocin Analog Compositions And Methods of Synthesizing The Same

      
Application Number 18141844
Status Pending
Filing Date 2023-05-01
First Publication Date 2023-08-31
Owner Mydecine Innovations Group Inc. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

  • C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
  • C07D 209/12 - Radicals substituted by oxygen atoms

17.

NOVEL PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME

      
Application Number US2023013928
Publication Number 2023/164203
Status In Force
Filing Date 2023-02-27
Publication Date 2023-08-31
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abstract

The present invention includes a novel class ofMDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

IPC Classes  ?

  • C07D 317/58 - Radicals substituted by nitrogen atoms
  • A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
  • A61P 25/00 - Drugs for disorders of the nervous system

18.

NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME

      
Application Number US2022031945
Publication Number 2023/101722
Status In Force
Filing Date 2022-06-02
Publication Date 2023-06-08
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

  • A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/00 - Medicinal preparations containing organic active ingredients

19.

NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME

      
Document Number 03210114
Status Pending
Filing Date 2022-06-02
Open to Public Date 2023-06-08
Owner MEDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61P 25/00 - Drugs for disorders of the nervous system

20.

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

      
Document Number 03209813
Status Pending
Filing Date 2022-07-14
Open to Public Date 2023-01-19
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Dr. Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

IPC Classes  ?

  • C07D 333/58 - Radicals substituted by nitrogen atoms
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
  • A61P 25/00 - Drugs for disorders of the nervous system
  • C07D 327/04 - Five-membered rings

21.

NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS

      
Application Number US2022037193
Publication Number 2023/288013
Status In Force
Filing Date 2022-07-14
Publication Date 2023-01-19
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Dr., Denton, W.
  • Roscow, Robert, F.

Abstract

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

IPC Classes  ?

  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
  • C07D 327/02 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom

22.

NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME

      
Document Number 03197923
Status Pending
Filing Date 2021-12-03
Open to Public Date 2022-06-09
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton W.
  • Roscow, Robert F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

23.

NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME

      
Application Number US2021061826
Publication Number 2022/120181
Status In Force
Filing Date 2021-12-03
Publication Date 2022-06-09
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Hoyer, Denton, W.
  • Roscow, Robert, F.

Abstract

The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

IPC Classes  ?

  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C07D 209/16 - Tryptamines

24.

NOVEL FUNGAL COMPOUND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE

      
Application Number US2021057017
Publication Number 2022/094054
Status In Force
Filing Date 2021-10-28
Publication Date 2022-05-05
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor Roscow, Robert, F.

Abstract

The present invention further relates generally to novel systems, methods, and compositions for generating pharmaceutical compositions and formulations that include one or more fungal compounds and/or extracts.

IPC Classes  ?

25.

NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF

      
Application Number US2021053136
Publication Number 2022/072808
Status In Force
Filing Date 2021-10-01
Publication Date 2022-04-07
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor
  • Gustin, John C
  • Mccarthy, Michael J.

Abstract

The present invention provides compositions and methods for the treatment of a serotonin receptor related disease or condition in a subject in need thereof. A composition of the invention includes at least one psychedelic compound, which is preferably a serotonin receptor agonist, and at least one secondary agent that modulates the activity of the serotonin receptor agonist, or the physiological response to the serotonin receptor agonist in the subject.

IPC Classes  ?

  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups

26.

NOVEL FORMULATIONS OF PSILOCYBIN AND PSILOCIN COMPOUNDS AS SEROTONIN AGONISTS IN COMBINATION WITH 3,4 METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

      
Application Number US2021051005
Publication Number 2022/061196
Status In Force
Filing Date 2021-09-18
Publication Date 2022-03-24
Owner MYDECINE INNOVATIONS GROUP INC. (USA)
Inventor Roscow, Robert, Fletcher

Abstract

The present invention is directed to the use of psilocybin and/or psilocin compounds in combination with 3,4-methylenedioxymethamphetamine (MDMA) or other entactogens, to modulate activity of serotonin receptors, and preferably the 5-HT2A serotonin receptor in humans. In certain preferred embodiment, the co-formulation of psilocybin and/or psilocin compounds in combination with MDMA may result in complex modulation activity of serotonin receptors in a subject in need thereof, and may be uses as a therapeutic treatment for one or more serotonin receptor related diseases or conditions.

IPC Classes  ?

  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/20 - HypnoticsSedatives
  • A61P 25/24 - Antidepressants
  • A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates

27.

MYDECINE MEDICINE EVOLVED

      
Serial Number 97289862
Status Registered
Filing Date 2022-03-01
Registration Date 2023-03-28
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

28.

M MYDECINE MEDICINE EVOLVED

      
Serial Number 97289912
Status Registered
Filing Date 2022-03-01
Registration Date 2023-03-28
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

29.

MYDECINE INNOVATIONS GROUP

      
Serial Number 97289971
Status Registered
Filing Date 2022-03-01
Registration Date 2023-03-28
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

30.

M MYDECINE INNOVATIONS GROUP

      
Serial Number 97289997
Status Registered
Filing Date 2022-03-01
Registration Date 2023-03-28
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

31.

M

      
Serial Number 97290054
Status Registered
Filing Date 2022-03-01
Registration Date 2023-03-28
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical and scientific research; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology; Testing of pharmaceuticals Psychotherapy; Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental health; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy services

32.

MYDECINE HEALTH SCIENCES

      
Serial Number 97267542
Status Registered
Filing Date 2022-02-15
Registration Date 2023-03-28
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Biological research; Biological research and analysis; Biomedical research services; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; Consulting services in the field of biotechnology; Development of pharmaceutical preparations and medicines; Genetic testing for scientific research purposes; Laboratory research in the field of mental health; Laboratory research in the field of mycology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of mental health; Medical and scientific research in the field of mycology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Product research and development; Providing information about medical research; Providing information about medical research in the field of mental health; Providing information about medical research in the field of mycology; Providing information about medical and scientific research; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Quality control for others; Research and development in the field of mental health; Research and development in the field of mycology; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of mental health; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, research and design in the field of mental health; Scientific and technological services, namely, research and design in the field of mycology; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mental health; Scientific and technological services, namely, scientific research, analysis, testing in the field of medical information, medical diagnostics, healthcare, computer technology, public health, and public health research in the field of mycology; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research and development; Scientific research in the field of genetics and genetic engineering; Testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others in the field of mental health; Scientific research in the nature of conducting clinical trials for others in the field of mycology Addiction treatment services; Advisory services relating to health care; Advisory services relating to health; Alternative medicine services; Clinical mental health counseling services; Consultancy services relating to health care; Drug use testing services; Health care; Health care consulting in the field of mental health; Health care services for treating mental illnesses; Health care services, namely, providing a database in the field of mental health information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of mycology information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care services, namely, pharmaceutical drug development services, medical research, biological research, product research and development and pharmaceutical research services; Health clinic services; Managed health care services; Medical services; Mental health services; Mental health therapy services; Providing mental health and wellness information; Psychotherapy; Psychotherapy services

33.

FUNGTIONAL

      
Serial Number 90160986
Status Registered
Filing Date 2020-09-04
Registration Date 2021-08-10
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Genetic testing for scientific research purposes; Product research and development; Research and development of technology in the field of mycology; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research and development Farming services in the field of fungi; Organic farming services in the field of fungi

34.

MYDECINE

      
Serial Number 90020592
Status Registered
Filing Date 2020-06-25
Registration Date 2021-01-19
Owner Mydecine Innovations Group Inc ()
NICE Classes  ?
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Genetic testing for scientific research purposes; Product research and development; Research and development of vaccines and medicines; Research and development of technology in the field of mycology; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research and development Farming services in the field of fungi; Organic farming services in the field of fungi